A Phase 4 interventional study of Gadoterate meglumine in Hepatocellular Carcinoma, sponsored by Guerbet. Terminated at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-08-08.
Sponsored by Guerbet · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of — 50 open to participants now, 74 under way, 8 of them phase 3. Carcinoma, Hepatocellular · Korea, Republic of.
Among the 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of, this one is the 196th largest by enrollment of the 255 interventional ones that give a count, is one of 22 that started in 2013, is one of 8 in phase 4, and was the 75th registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →50 of the 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
CHA University · Sites in Korea, Republic of
Ages 19+
National Cancer Center, Korea · Sites in Korea, Republic of
Ages 19–79
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
AstraZeneca · Sites in Korea, Republic of, Australia, Georgia and 2 more countries
Ages 18+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
298 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 54 · Phase 2 114 · Phase 3 49 · Phase 4 8
First in 2002; this study’s year is marked. 22 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 87 across the 255 interventional studies, 200 across the 43 observational. Of the 183 that completed or were terminated, 64 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
145 of 298 have an industry lead sponsor. The 10 most frequent:
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Guerbet has 4 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
23 of the studies in Carcinoma, Hepatocellular with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05822752AbbVieStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | 2026-11 |
| NCT07252323Yonsei UniversityA Single-arm Phase II Clinical Study Investigating the Safety and Efficacy of Carbon Ion Radiotherapy in Patients With Hepatocellular Carcinoma Previously Treated With Transarterial Radioembolization (TARE) | 2026-11 |
| NCT06178198Seoul National University HospitalRadiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma | 2026-11-30 |
| NCT05433701Jonggi ChoiStereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCC | 2026-12-31 |
| NCT07186010Asan Medical CenterImmunogenomic Dynamics and Biomarkers in Patients With Hepatocellular Carcinoma Receiving Immunotherapy | 2026-12-31 |
Add all 23 to your calendar (.ics) → With an account.
Among the 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective is to evaluate the value of dynamic contrast-enhanced Magnetic Resonance Imaging (DCE-MRI) in prediction of response of patients with hepatocellular carcinoma (HCC) to treatment with Sorafenib assessed by mRECIST.
One of the secondary objectives was to evaluate the correlation between DCE-MRI perfusion parameters at baseline and:
Three DCE-MRI examinations were done during the study:
DCE-MRI perfusion parameters were assessed by a centralized radiologist at baseline (corresponding to the day of enrolment and initiation of Sorafenib treatment), week 1 and week 2.
According to mRECIST criteria, HCC lesions were evaluated on computed tomography images by two on-site radiologists at the time of enrolment and 8 weeks later (2 months). OS, PFS and TTP were calculated from survival and tumor progression data recorded one year after initiation of the sorafenib treatment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iRECIST and mRECIST
Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
there is one single arm of patients (no comparative arm)
Drug: Gadoterate meglumine
Gadoterate meglumine was administered at a dose of 0.1 mmol/kg (0.2 mL/kg) using a power injector, in an intravenous bolus at a rate of 3 mL/sec.
Also known as: gadoteric acid, Dotarem
Correlation Coefficient Between DCE-MRI Perfusion Parameters and the Response of Target Lesions to Sorafenib
To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, Wash-in, Washout) at baseline, week 1 and week 2, and the response of target lesions to sorafenib. * Ktrans: volume transfer constant between blood plasma and extravascular extracellular space * AUC : area under the curve of tissue gadolinium concentration-time * ve: fractional volume of extravascular extracellular space * kep: rate constant between extravascular extracellular space and blood plasma (=Ktrans/ve) * T1: longitudinal relaxation time * Wash-in: slope of the early enhancement curve * Washout: slope of the late enhancement curve The response of target lesions was assessed by mRECIST at 2 months after initiation of treatment (sorafenib). The correlation analyses were done using Pearson or Spearman correlation coefficient.
Time frame: 3 months
Correlation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Overall Survival
To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, wash-in, washout) at baseline and overall survival. The overall survival was calculated from the patient's survival status recorded one year after initiation of the sorafenib treatment. The correlation analyses were done using Pearson or Spearman correlation coefficient.
Time frame: 1 year
Correlation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Progression Free Survival
To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, wash-in, washout) at baseline and progression free survival. The progression free survival was calculated from the patient's survival status and tumor progression status recorded one year after initiation of the sorafenib treatment. The correlation analyses were done using Pearson or Spearman correlation coefficient.
Time frame: 1 year
Correlation Coefficient Between DCE-MRI Perfusion Parameters at Baseline and Time to Progression
To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, wash-in, washout) at baseline and time to progression. The time to progression was calculated from the patient's survival status and tumor progression status recorded one year after initiation of the sorafenib treatment. The correlation analyses were done using Pearson or Spearman correlation coefficient.
Time frame: 1 year
Despite several extensions of the recruitment period, the planned number of enrolled patients was still not reached after 2 years and the study was prematurely discontinued. A total of 37 patients were enrolled in four study sites.
| Milestone | Gadoterate Meglumine |
|---|---|
| Started | 37 |
| Completed | 31 |
| Not completed | 6 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Physician decision | 1 |
| Withdrew: Patient's refusal of treatment | 1 |
To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, Wash-in, Washout) at baseline, week 1 and week 2, and the response of target lesions to sorafenib. * Ktrans: volume transfer constant between blood plasma and extravascular extracellular space * AUC : area under the curve of tissue gadolinium concentration-time * ve: fractional volume of extravascular extracellular space * kep: rate constant between extravascular extracellular space and blood plasma (=Ktrans/ve) * T1: longitudinal relaxation time * Wash-in: slope of the early enhancement curve * Washout: slope of the late enhancement curve The response of target lesions was assessed by mRECIST at 2 months after initiation of treatment (sorafenib). The correlation analyses were done using Pearson or Spearman correlation coefficient.
| correlation coefficient | Baseline | Week 1 | Week 2 |
|---|---|---|---|
| Ktrans (mean) | -0.29 | -0.38 | -0.38 |
| AUC (mean) | -0.53 | -0.60 | -0.62 |
| ve (mean) | -0.19 | -0.33 | -0.34 |
| kep (mean) | -0.07 | -0.24 | -0.17 |
| T1 (mean) | 0.05 | 0.30 | 0.18 |
| Wash-in (mean) | -0.42 | -0.48 | -0.52 |
| Washout (mean) | -0.31 | -0.48 | -0.36 |
To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, wash-in, washout) at baseline and overall survival. The overall survival was calculated from the patient's survival status recorded one year after initiation of the sorafenib treatment. The correlation analyses were done using Pearson or Spearman correlation coefficient.
| correlation coefficient | Baseline |
|---|---|
| Ktrans (mean) | 0.09 |
| AUC (mean) | -0.08 |
| ve (mean) | 0.35 |
| kep (mean) | -0.05 |
| T1 (mean) | -0.14 |
| Wash-in (mean) | -0.02 |
| Washout (mean) | -0.04 |
To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, wash-in, washout) at baseline and progression free survival. The progression free survival was calculated from the patient's survival status and tumor progression status recorded one year after initiation of the sorafenib treatment. The correlation analyses were done using Pearson or Spearman correlation coefficient.
| correlation coefficient | Baseline |
|---|---|
| Ktrans (mean) | -0.24 |
| AUC (mean) | -0.45 |
| ve (mean) | 0.17 |
| kep (mean) | -0.23 |
| T1 (mean) | -0.15 |
| Wash-in (mean) | -0.31 |
| Washout (mean) | -0.29 |
To evaluate the correlation between DCE-MRI perfusion parameters (Ktrans, AUC, ve, kep, T1, wash-in, washout) at baseline and time to progression. The time to progression was calculated from the patient's survival status and tumor progression status recorded one year after initiation of the sorafenib treatment. The correlation analyses were done using Pearson or Spearman correlation coefficient.
| correlation coefficient | Baseline |
|---|---|
| Ktrans (mean) | -0.72 |
| AUC (mean) | -0.64 |
| ve (mean) | -0.68 |
| kep (mean) | -0.17 |
| T1 (mean) | 0.24 |
| Wash-in (mean) | -0.70 |
| Washout (mean) | -0.42 |
Collected over 3 months (from the informed consent signature to 2 months after initiation of the sorafenib treatment). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gadoterate Meglumine | 1/31 (3.2%) | 7/31 (22.6%) | 29/31 (93.5%) |
| Event | Gadoterate Meglumine |
|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/31 |
| Abdominal pain upperGastrointestinal disorders | 1/31 |
| Tumor necrosisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/31 |
| Gastric varices haemorrhageGastrointestinal disorders | 1/31 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 1/31 |
| Upper respiratory tract infectionInfections and infestations | 1/31 |
| Hepatic encephalopathyNervous system disorders | 1/31 |
| Cholecystitis acuteHepatobiliary disorders | 1/31 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/31 |
| Event | Gadoterate Meglumine |
|---|---|
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 15/31 |
| DiarrhoeaGastrointestinal disorders | 10/31 |
| NauseaGastrointestinal disorders | 6/31 |
| Abdominal painGastrointestinal disorders | 5/31 |
| RashSkin and subcutaneous tissue disorders | 4/31 |
| Abdominal pain upperGastrointestinal disorders | 3/31 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/31 |
| Blood pressure increasedInvestigations | 3/31 |
| HeadacheNervous system disorders | 3/31 |
| Decreased appetiteMetabolism and nutrition disorders | 3/31 |
| Age, Continuous(years) | Gadoterate Meglumine |
|---|---|
| Mean | 60.06 ± 10.78 |
| Sex: Female, Male(Participants) | Gadoterate Meglumine |
|---|---|
| Female | 4 |
| Male | 27 |
| Race (NIH/OMB)(Participants) | Gadoterate Meglumine |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 31 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Weight(kg) | Gadoterate Meglumine |
|---|---|
| Mean | 60.03 ± 9.17 |
Plan to share: Undecided — It will be decided after study completion.
No publications or documents are linked to this record.
Ran from May 2013 to primary completion in Oct 2015, 29 months.
Results were first posted in Aug 2019, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadoterate meglumine